Cancer treatment protocols,
at the speed of care.
Clinical Decision Support · Oncology
An AI-powered tool that helps oncologists generate accurate, evidence-based breast cancer treatment protocols; from patient data to post-treatment review, aligned with MOHAP, DHA, NCCN, NHS & BCCA guidelines.
70%
Reduction in protocol
planning time
X2
Patient throughput
per tumour board
94%
Guideline alignment
score
+10%
Mortality risk per 4-week
treatment delay
Aligned with:
> MOHAP Digital Health Strategy > DHA Guidelines & Cabinet Resolution No. 28/2020 > NCCN · NHS · BCCA Protocols > Phase 2 & 3 Clinical Trial Data > Built with oncology clinical advisors
See it in action.
Product Demo - Watch how SensAI Medical generates a breast cancer treatment protocol, from patient data input to clinician-ready output, in under five minutes.
End-to-end support across the full care pathway.
What it does - From first diagnosis to post-treatment review; SensAI covers every stage of the breast cancer treatment lifecycle.
Patient data to protocol
Ingests patient-specific inputs; stage, receptor status, comorbidities, imaging; and generates a fully referenced, guideline-aligned treatment protocol in minutes.
Global guideline synthesis
Cross-references NCCN, NHS, BCCA, MOHAP and DHA guidelines simultaneously; giving clinicians the most current evidence base without manual lookup.
Traceable, editable, explainable
Every recommendation is explainable and editable. Doctors remain in control; the AI provides a structured starting point, not a fixed answer.
Doctor/patient lifecycle - SensAI supports every step of the clinical pathway.
01
Patient presents with symptoms or referral
02
Doctor diagnoses stage, receptor status, imaging confirmed
03
Board of doctors. Tumour board reviews AI-generated protocol
04
Doctor treats approved protocol initiated with full documentation
05
Patient diagnosis. Ongoing monitoring and response tracking
06
Treatment modification. Protocol adjusted based on outcomes, with full audit trail
Breast cancer is the #1 cancer in the UAE. The system isn't keeping pace.
The problem & the fix - 1,456 new cases in 2023. Manual planning causes delays, variability, and inequity; across every hospital type.
Problem
-
AI cross-references NCCN, NHS, BCCA and DHA simultaneously. The board starts from a validated, structured baseline.
-
Every facility (public, private, or charity) generates the same guideline-aligned protocol. Care quality no longer depends on location.
-
Treatment starts sooner. DHA reporting and full audit trails are generated with every protocol, no separate admin step required.
Sensai Solution
-
Senior oncologists manually compile protocols from multiple guidelines. Junior doctors draft from memory, then wait for senior sign-off.
-
77% of patients are Non-Emirati; many are treated in under-resourced facilities with no consistent care standard. A 2.9% survival gap results.
-
In a manual system, delays are structural. Regulatory reporting under Cabinet Resolution No. 28/2020 adds further administrative burden.
Value across every stakeholder in care.
-
Faster treatment = higher survival
Protocol generation eliminates weeks of manual preparation, directly reducing mortality risk.
Personal evidence-based care
Tailored to patient-specific data; reducing unnecessary treatments and readmissions.
Equal care, any facility
Public or private, every patient receives the same gold-standard, guideline-aligned protocol.
-
70% less preparation time
Automated protocol generation frees oncologists from manual guideline lookup.
Senior performance at every level
Junior doctors apply gold-standard protocols confidently; reducing senior staffing dependency.
Lower medico-legal risk
Traceable, auditable AI outputs; every decision logged and legally defensible.
-
2× Patient throughput
Higher case volume per doctor, without increasing headcount or costs.
Audit - Ready by default
DHA-compliant, Cabinet Resolution No. 28/2020 reporting; automatic with every protocol.
Zero - Protocol errors
Eliminates misdiagnosis pathways and the litigation exposure that follows.
-
MOHAP & DHA aligned
Supports UAE digital health strategy; scalable public-private AI adoption from day one.
2.9% survival gap closed
National protocol alignment reduces the regional survival disparity across UAE facilities.
£3.6B Burden reduced
Standardised, outcome-driven care reduces the national economic cost of breast cancer.
Not a single-user tool, a system-level upgrade for the entire oncology pathway.
Built for regulated clinical environments.
Governance & compliance - For medical buyers, compliance is not a feature, it's a prerequisite.
Data residency
& security
Deployable on AWS, GCP, or hybrid environments within UAE jurisdiction. Patient data never leaves your infrastructure.
Cabinet Resolution
No. 28/2020
DHA mandatory reporting and data traceability are satisfied automatically. Audit-ready outputs with every protocol; no separate admin step.
Liability
positioning
SensAI is a decision support tool. Clinician sign-off is mandatory. Liability stays with the treating physician; AI assists, it does not decide.
This is a 6–12 month
deployment, not a SaaS.
Work with us - We work directly with oncology departments and hospital leadership to scope, validate, and pilot SensAI Medical; starting with your tumour board workflow.
Pilot programs include clinical validation, workflow integration, and a governance framework aligned to your institution.